AU2007261561B2 - Regulation of protein activity by reversible acetylation - Google Patents

Regulation of protein activity by reversible acetylation Download PDF

Info

Publication number
AU2007261561B2
AU2007261561B2 AU2007261561A AU2007261561A AU2007261561B2 AU 2007261561 B2 AU2007261561 B2 AU 2007261561B2 AU 2007261561 A AU2007261561 A AU 2007261561A AU 2007261561 A AU2007261561 A AU 2007261561A AU 2007261561 B2 AU2007261561 B2 AU 2007261561B2
Authority
AU
Australia
Prior art keywords
acecs2
polypeptide
sirt3
activity
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007261561A
Other languages
English (en)
Other versions
AU2007261561A1 (en
Inventor
Bjoern Schwer
Eric Verdin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J David Gladstone Institutes
Original Assignee
J David Gladstone Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J David Gladstone Institutes filed Critical J David Gladstone Institutes
Publication of AU2007261561A1 publication Critical patent/AU2007261561A1/en
Application granted granted Critical
Publication of AU2007261561B2 publication Critical patent/AU2007261561B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007261561A 2006-06-12 2007-06-12 Regulation of protein activity by reversible acetylation Ceased AU2007261561B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81327506P 2006-06-12 2006-06-12
US60/813,275 2006-06-12
US11/761,198 2007-06-11
US11/761,198 US8518635B2 (en) 2006-06-12 2007-06-11 Regulation of protein activity by reversible acetylation
PCT/US2007/013804 WO2007149270A2 (en) 2006-06-12 2007-06-12 Regulation of protein activity by reversible acetylation

Publications (2)

Publication Number Publication Date
AU2007261561A1 AU2007261561A1 (en) 2007-12-27
AU2007261561B2 true AU2007261561B2 (en) 2013-02-28

Family

ID=38833973

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007261561A Ceased AU2007261561B2 (en) 2006-06-12 2007-06-12 Regulation of protein activity by reversible acetylation

Country Status (8)

Country Link
US (1) US8518635B2 (https=)
EP (1) EP2029731B1 (https=)
JP (1) JP2009542195A (https=)
AT (1) ATE543902T1 (https=)
AU (1) AU2007261561B2 (https=)
CA (1) CA2654458A1 (https=)
ES (1) ES2380248T3 (https=)
WO (1) WO2007149270A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171809A1 (en) 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
CA2645853A1 (en) 2006-03-31 2007-11-01 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
JP6352924B2 (ja) 2012-09-19 2018-07-04 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ダイナミックｂｈ３プロファイリング
AU2014323526B2 (en) 2013-09-19 2020-07-23 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
EP3288964B1 (en) 2015-04-27 2024-02-21 Dana-Farber Cancer Institute, Inc. High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
EP3931563A4 (en) 2019-02-26 2022-12-21 Dana-Farber Cancer Institute, Inc. BH3 DYNAMIC PROFILING FOR LIVING CELL IMAGING
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US82668A (en) * 1868-09-29 Thomas b
US120008A (en) * 1871-10-17 Improvement in apparatus for feeding pulverized fuel to metallurgical and other furnaces
JP2001149081A (ja) 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
US20020120008A1 (en) 2000-06-29 2002-08-29 Seymour Benzer Life extension of drosophila by a drug treatment
WO2002102981A2 (en) 2001-06-15 2002-12-27 The Trustees Of Columbia University In The City Of New York SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
WO2002102316A2 (en) * 2001-06-19 2002-12-27 The Regents Of The University Of California Histone deacetylase and methods of use thereof
WO2003004621A2 (en) 2001-07-06 2003-01-16 Elixir Pharmaceuticals, Inc. Sir2 activity
US7351542B2 (en) * 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
CA2417033A1 (en) 2003-01-23 2004-07-23 Paul Kerr External support structure for use in the transporting of manufactured houses
US7272713B1 (en) * 2003-10-22 2007-09-18 Symantec Corporation Controlling file operations
WO2005062952A2 (en) * 2003-12-23 2005-07-14 The Regents Of The University Of California Compositions and methods for modulating sirtuin activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHWER, B., et al., Proceedings of the National Academy of Science, USA., 2006, vol. 103, pages 10224-10229 *

Also Published As

Publication number Publication date
CA2654458A1 (en) 2007-12-27
ATE543902T1 (de) 2012-02-15
EP2029731A2 (en) 2009-03-04
WO2007149270A3 (en) 2008-10-30
ES2380248T3 (es) 2012-05-09
WO2007149270A9 (en) 2008-03-06
WO2007149270A2 (en) 2007-12-27
US8518635B2 (en) 2013-08-27
EP2029731A4 (en) 2009-10-21
AU2007261561A1 (en) 2007-12-27
JP2009542195A (ja) 2009-12-03
US20090061015A1 (en) 2009-03-05
EP2029731B1 (en) 2012-02-01

Similar Documents

Publication Publication Date Title
Yu et al. Deubiquitinase OTUB2 exacerbates the progression of colorectal cancer by promoting PKM2 activity and glycolysis
Nguyen et al. The MARCHF6 E3 ubiquitin ligase acts as an NADPH sensor for the regulation of ferroptosis
AU2007261561B2 (en) Regulation of protein activity by reversible acetylation
Zhong et al. AAA ATPase p97/valosin-containing protein interacts with gp78, a ubiquitin ligase for endoplasmic reticulum-associated degradation
Xie et al. Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells
Zhang et al. Deacetylation of cortactin by SIRT1 promotes cell migration
Perrone et al. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions
van Huizen et al. P58IPK, a novel endoplasmic reticulum stress-inducible protein and potential negative regulator of eIF2α signaling
Anselmo et al. WNK1 and OSR1 regulate the Na+, K+, 2Cl− cotransporter in HeLa cells
Pereira et al. IMPACT, a protein preferentially expressed in the mouse brain, binds GCN1 and inhibits GCN2 activation
Wang et al. A role for 14-3-3τ in E2F1 stabilization and DNA damage-induced apoptosis
Duterme et al. Two novel functions of hyaluronidase-2 (Hyal2) are formation of the glycocalyx and control of CD44-ERM interactions
Shibata et al. p47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO
Liu et al. Discovery of small-molecule inhibitors of the HSP90-calcineurin-NFAT pathway against glioblastoma
Figlia et al. Brain-enriched RagB isoforms regulate the dynamics of mTORC1 activity through GATOR1 inhibition
US20110287026A1 (en) Sirt4 and uses thereof
CN101490250A (zh) 通过可逆乙酰化调节蛋白质活性
Vilema-Enríquez et al. Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich's ataxia patient cells
Li et al. DCAF7 acts as a scaffold to recruit USP10 for G3BP1 deubiquitylation and facilitates chemoresistance and metastasis in nasopharyngeal carcinoma
Natale et al. Inhibition of zDHHC7-driven protein S-palmitoylation prevents cognitive deficits in an experimental model of Alzheimer’s disease
Wu et al. Regulation of the urea cycle by CPS1 O-GlcNAcylation in response to dietary restriction and aging
Zhang et al. Oncometabolite 5-IP7 inhibits inositol 5-phosphatase to license E-cadherin endocytosis
Yang et al. HSP90 N‐terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2‐driven breast cancer progression
Fang et al. Glucose-mediated N-glycosylation of RPTPα affects its subcellular localization and Src activation
Sha et al. The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired